Skip to main content
Premium Trial:

Request an Annual Quote

Karin Eastham, Robert Brown, Marsha Fanucci, Kenneth Bate, Patti Doherty, Steve Lombardi, Leslie Brown, R.B. Woodward


Illumina has appointed Karin Eastham to its board of directors. She is currently executive vice president, chief operating officer, and a member of the board of trustees of the Burnham Institute. She is also a director of Tercica, Oncosis/Cyntellect, and Salmedix. Eastham received a BS and MBA from Indiana University.

Serologicals has hired Robert Brown as vice president of corporate development. Brown comes to Serologicals from Andrx, where he was senior vice president for corporate development. He has a BS in chemistry from Neumann College.

Millennium Pharmaceuticals has promoted Marsha Fanucci, senior vice president of finance and corporate strategy, to senior vice president and chief financial officer.

Fanucci will still oversee corporate strategy, the treasury, and financial planning and reporting, and will also be responsible for information technology at the company.

She succeeds Kenneth Bate, executive vice president and head of commercial operations, who will continue to report to the CEO. He will also oversee commercial manufacturing and quality assurance at Millennium.

Fanucci joined Millennium in 2000 from Genzyme, where she was a vice president for corporate development and strategy. She has a BS in pharmacy from West Virginia University and an MBA from Northeastern University.

Exagen Diagnostics has hired Patti Doherty as director of clinical studies, a newly created position. Doherty, a registered nurse, will run research and development of Exagen’s gene-based prognostic tests.

IntegraGen has named Steve Lombardi non-executive director, the company said. Lombardi is currently senior vice president of corporate development at Affymetrix, and spent 16 years at Applied Biosystems, where he rose to become senior vice president of applications and products.

Pharmacopeia Drug Discovery has named Leslie Brown as president and chief executive officer, the company announced last week.

Most recently, Brown served as chief operating officer at Iconix Pharmaceuticals. He has also been the chief operating officer at functional genomics company GeneTrace. From 1990 to 2000, Brown held a number of senior positions at Berlex/Schering AG including corporate vice president of Berlex Labs and president of Schering Berlin Venture.

Brown received his PhD from the University of Michigan, and was an NIH postdoctoral fellow at Harvard with Nobel laureate professor R.B. Woodward.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.